Clinical Experience of the Long-term Use of Pirfenidone for Idiopathic Pulmonary Fibrosis-Reference-Cited by-同舟云学术

Clinical Experience of the Long-term Use of Pirfenidone for Idiopathic Pulmonary Fibrosis

Published:2016 Issue:5 Volume:55 Page:443-448
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Bando Masashi¹,Yamauchi Hiroyoshi¹,Ogura Takashi²,Taniguchi Hiroyuki³,Watanabe Kentaro⁴,Azuma Arata⁵,Homma Sakae⁶,Sugiyama Yukihiko¹,The Japan Pirfenidone Clinical Study Group

Affiliation:

1. Division of Pulmonary Medicine, Department of Medicine, Jichi Medical University, Japan

2. Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Japan

3. Department of Respiratory Medicine and Allergy, Tosei General Hospital, Japan

4. Department of Respiratory Medicine, Fukuoka University School of Medicine, Japan

5. Division of Pulmonary Medicine, Infection and Oncology, Nippon Medical School, Japan

6. Department of Respiratory Medicine, Toho University Omori Medical Center, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/55/5/55_55.5272/_pdf

Reference13 articles.

1. 1. Raghu G, Collard HR, Egan JJ, et al; on behalf of the ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183: 788-824, 2011.

2. 2. Diagnosis and treatment guidance of idiopathic interstitial pneumonia. 2nd ed. The Japanese Respiratory Society Diagnosis and Treatment Guidelines Construction Committee, Ed. Nankodo, Tokyo, 2011 (in Japanese).

3. 3. Azuma A. Pirfenidone treatment of idiopathic pulmonary fibrosis. Ther Adv Respir Dis 6: 107-114, 2012.

4. 4. Oku H, Shimizu T, Kawabata T, et al. Antifibrotic action of pirfenidone and prednisolone: Different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 590: 400-408, 2008.

5. 5. Taniguchi H, Ebina M, Kondoh Y, et al; the Pirfenidone Clinical Study Group in Japan. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 35: 821-829, 2010.

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Harnessing the translational power of bleomycin model: new insights to guide drug discovery for idiopathic pulmonary fibrosis;Frontiers in Pharmacology;2023-11-30

2. Significant functional improvement in IPF patient treated with antifibrotic drugs: preliminary results and clinical outcome;Minerva Medica;2023-11

3. Real world experience on the effectiveness and safety of pirfenidone in patients with idiopathic pulmonary fibrosis in Taiwan;Frontiers in Medicine;2023-10-30

4. Improved Survival of IPF patients Treated With Antifibrotic Drugs Compared With Untreated Patients;Lung;2023-06-21

5. Idiopathic Pulmonary Fibrosis: 8 Years On After Nintedanib and Pirfenidone Approval—What Is on the Horizon?;Current Pulmonology Reports;2023-06-20